سعر سوليكا 100 وحدة 50مكجم/مل 3 اقلام معبأة 3 مل 2024

Fixed-ratio combination of insulin glargine 100 units/ml and lixisenatide 50 mcg/ml in 3 ml pre-filled pens (pack of 3), for subcutaneous injection once daily.

• Adults with insufficiently controlled type 2 diabetes mellitus, adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitorsPopulation: AdultsEuropean Medicines Agency (EMA)

• Most frequent: hypoglycaemia and gastrointestinal reactions (nausea 8.4%, diarrhoea 2.2%, vomiting 2.2%, mostly mild and transient); also dizziness, headache, dyspepsia, abdominal pain, injection-site reactions, nasopharyngitis, urticaria; rare delayed gastric emptying; lipodystrophy and cutaneous amyloidosis reported.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to insulin glargine, lixisenatide or any excipient.International label, same formulation · European Medicines Agency (EMA)
• US label: contraindicated during episodes of hypoglycaemia and in serious hypersensitivity to insulin glargine, lixisenatide or excipients.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Not for type 1 diabetes or diabetic ketoacidosis. Hypoglycaemia is the most frequent adverse reaction; risk factors (missed meals, exercise, alcohol, illness, injection-site change) need close monitoring.International label, same formulation · European Medicines Agency (EMA)
• Rotate injection sites: injecting into areas of lipodystrophy or cutaneous amyloidosis may delay insulin absorption; switching to an unaffected site can cause hypoglycaemia.International label, same formulation · European Medicines Agency (EMA)
• US label: acute pancreatitis has been observed with GLP-1 receptor agonists including SOLIQUA 100/33 (discontinue if suspected); never share pens between patients; serious hypersensitivity including anaphylaxis can occur.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Medicines that enhance glucose lowering (antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, salicylates, sulphonamide antibiotics)May increase hypoglycaemia risk; dose adjustment may be needed.European Medicines Agency (EMA)
• Medicines that reduce glucose lowering (corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens/progestogens, phenothiazines, somatropin, sympathomimetics, thyroid hormones, atypical antipsychotics, protease inhibitors)May reduce the blood-glucose-lowering effect; dose adjustment may be needed.European Medicines Agency (EMA)
• Beta-blockers, clonidine, lithium, alcohol, pentamidineMay potentiate or weaken glucose lowering; sympatholytics may mask hypoglycaemia warning signs.European Medicines Agency (EMA)

• Not recommended during pregnancy or in women of childbearing potential not using contraception: no clinical data for the combination; large data for insulin glargine show no malformative toxicity, but lixisenatide showed reproductive toxicity in animals.International label, same formulation · European Medicines Agency (EMA)
• US label: animal studies suggest possible fetal risk from lixisenatide; use in pregnancy only if the potential benefit justifies the potential risk; poorly controlled diabetes itself carries maternal and fetal risks.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Unknown whether excreted in human milk; breastfeeding should be discontinued during treatment.International label, same formulation · European Medicines Agency (EMA)

• Insulin glargine: Regulates glucose metabolism: stimulates peripheral glucose uptake and inhibits hepatic glucose production (EU SmPC 5.1).
• Lixisenatide: GLP-1 receptor agonist that potentiates glucose-dependent insulin secretion and suppresses glucagon, mainly lowering postprandial glucose (EU SmPC 5.1).